The convenience of pre-mixed liquid comes with a trade-off
There are currently no clinical trials investigating the use of GLP-1RAs in patients with PTSD or OCD, leaving the clinical validation of these findings unexplored
The turning point appears to happen around the two-month mark
Expertise in Carbon Markets and ACCUs The LGI team applies proven capability to optimise biogas extraction for carbon abatement and creation of Australian Carbon Credit Units (ACCUs), as well as to generate renewable energy and large scale renewable credits (LGCs)
With 124 anti-obesity drugs in the development pipeline, treatment options are increasing, which could help ease access and lower costs
Intestinal obstruction Recent reports have led to the FDA updating labeling for some GLP-1 agonists, including Ozempic, to include a warning about intestinal blockage (ileus)